Tags : Innovent Biologics

Biosimilars Insights+

Insights+ Key Biosimilars Events of January 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilar is expanding its footprints worldwide with multiple collaborations. In Jan 2020, Pfizer launched its two biosimilars [Ruxience (biosimilar, rituximab) & Trazimera (biosimilar, trastuzumab)] at lowest WAC in the US Our team at PharmaShots has summarized key […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (January 13-17, 2020)

1. Arena’s APD418 Receives FDA’s Fast Track Designation to Treat Patients with Decompensated Heart Failure Published: Jan 17, 2020 | Tags: Arena, APD418, Receives, FDA, Fast Track Designation, Treat, Patients, Decompensated Heart 2. Charles River Collaborates with Fios Genomics for Bioinformatics-Driven Drug Discovery and Safety Assessment Published: Jan 16, 2020 | Tags: Charles River, Collaborates, Fios Genomics, […]Read More


Insights+ Key Biosimilars Events of August 2019

Biosimilars are key alternatives for costly Biologics therapies and saving million dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars “a reference product to biologics” possessing similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots has summarized key events of biosimilar space […]Read More

Biosimilars Biotech Pharma

Innovent Biosciences Collaborates with Chipscreen to Evaluate Chidamide in Combination

Shots: The companies collaborated to jointly assess safety and efficacy of Chipscreen’s Chidamide in combination with Innovent’s Sintilimab + IBI305 in patients with advanced colorectal carcinoma (ACC) The focus of the agreement is to explore the combination in clinical applications of immune check-point inhibitor, angiogenesis inhibitor and epigenetic modulator in ACC  Chidamide is a HDAC […]Read More

Biosimilars Biotech

Innovent Biologics Reports Acceptance of BLA for IBI-305 (bevacizumab, biosimilar)

Shots: The BLA is based on two P-III study results assessing efficacy, safety and PK of IBI-305 vs bevacizumab in patients with advanced non-sq NSCLC and has demonstrated in meeting 1EPs with bio-similarity Innovent has received three NMPA acceptance including IBI-305 namely Tyvyt (sintilimab injection) and IBI-303 (adalimumab, biosimilar) in H2’18 for ankylosing spondylitis (AS), […]Read More


Innovent Biologics and Eli Lilly’s Tyvyt (Sintilimab injection) Receives NMPA

Shots: The approval is based on ORIENT-1 study results assessing Tyvyt in patients with 2L+ Hodgkin’s lymphoma The ORIENT-1 study resulted in effective complete response rates for CT + radiotherapy in patients Tyvyt is an IgG4 mAb, which helps in binding with PD-1 in T cells further blocking PD-L1. In 2015, Innovent Biologics and Eli Lilly collaborated to […]Read More